Business Wire

NY-IL-MAKIAGE/VOYAGE81

12.8.2021 14:02:08 CEST | Business Wire | Press release

Share
IL MAKIAGE Acquires Leading Israeli Computer Vision Startup Voyage81

IL MAKIAGE, the fastest growing beauty company in the U.S., today announces the acquisition of Voyage81, a deep-tech AI-based computational imaging startup. IL MAKIAGE’s acquisition of Voyage81 will enable the company to use Voyage81’s patented hyperspectral imaging systems to further enhance the company’s machine learning capabilities and aligns with IL MAKIAGE's commitment to continue innovating and revolutionizing the beauty and wellness industries at-large. It also sets the stage for the company’s planned new brand launches within the beauty and wellness domains. The acquisition is the company’s second technology acquisition in the last 24 months.

Voyage81 is the first and only company in the world to develop patented software that brings hyperspectral imaging capabilities to smartphones. Voyage81’s software extracts over 30 channels of hyperspectral information from RGB images taken with existing smartphone cameras. In addition to its vision software, Voyage81 is currently developing a hardware-based solution, in tandem with some of the largest global smartphone manufacturers, that builds on the company’s hyperspectral software to significantly enhance photos taken in low-light conditions.

IL MAKIAGE CEO Oran Holtzman says, “For the past two years, we have been searching for computational imaging solutions that can work in beauty and wellness to further advance our existing AI capabilities. I have met dozens of computer vision startups but could not find a technology that can fit our industry and was strong enough to fulfill our goals. Bringing on Voyage81’s patented technology and exceptional team to our tech and data science departments is a huge win for our company's future, our users, and the industry at-large."

The implications of Voyage81's technology for the beauty and wellness industries are endless. Voyage81’s software is capable of mapping and analyzing skin and hair features, detecting facial blood flows, and creating melanin and hemoglobin maps from a simple smartphone camera photo. The technology, combined with IL MAKIAGE’s current AI algorithms, will leverage users' personal smartphone cameras to provide unparalleled online matching capabilities to users of IL MAKIAGE and its upcoming homegrown digital beauty and wellness brands.

Voyage81 was founded in 2019 by CEO Niv Price, former head of R&D at Unit 81, the most elite technological unit in the Israeli Defense Forces (the unit’s alumnus are known to have founded some of the most successful start-ups in Israel), Dr. Boaz Arad (CTO), a Ph.D. in Computer Vision and a key opinion leader in the hyperspectral space, Dr. Rafi Gidron, an accomplished and well-known Israeli hi-tech serial entrepreneur (including Chromatis Networks, sold to Lucent), and Omer Shwartz (Software Lead), a Ph.D. in Cyber Security.

Voyage81’s computer vision capabilities and team (half of whom hold PhDs) will be integrated within IL MAKIAGE's data science capabilities and its matching algorithms to serve the company's tens of millions of users and customers. Voyage81 founders, Niv Price, Dr. Arad and Omer Shwartz, will take leadership roles in IL MAKIAGE. Price will serve as CTO, Dr. Arad will serve as Chief Vision Officer, while Shwartz will serve as VP of Information Security. All three will also continue to lead Voyage81 as CEO, CTO and Software Lead.

“When we met Oran, we were focused on our own rapid growth trajectory with no plans at all to sell," notes Price, Voyage81 co-founder and CEO. "In fact, we just finished round A funding and were already working with the largest smartphone manufacturers in the world. But after meeting Oran and learning about the company’s long-term vision, we realized that under the IL MAKIAGE platform, Voyage81 technology will serve and benefit hundreds of millions of consumers, fulfilling our founding goal.”

"The technological advancements for IL MAKIAGE are immense," said Holtzman. "The software-only hyperspectral expansion, which requires only a traditional image from any smartphone camera, will be immediately integrated into the company's consumer experience. The addition of these vision capabilities provides another dimension of information which will allow us to rapidly expand our capabilities in existing and future domains with lower amount of data needed for our machine learning models."

Voyage81 co-founder and CTO, Dr. Arad said, “Combining Voyage81’s physics-based algorithms with IL MAKIAGE’s existing data science team and utilizing the company’s one billion+ data points and unprecedented daily incoming data flow, will further boost our AI vision capabilities. Thus, I strongly believe that together we can conquer the next frontier in the beauty and wellness industries – creating a technological advantage that will be next to impossible to match.”

Voyage81’s technology was developed based on the doctoral research of Dr. Arad who was examining by how much the estimation of hyperspectral information from RGB data would be inferior to professional hyperspectral camera results. When he saw that the results were almost comparable, he thought he had introduced some errors into the comparison process, but after deep investigation he realized he was on to an exciting discovery that has the potential to reverberate throughout the world.

About IL MAKIAGE
Launched in the US in 2018 by brother-sister duo entrepreneurs, IL MAKIAGE is a New York based, tech-driven prestige DTC beauty company. IL MAKIAGE is defining and building the future of beauty by using proprietary technology to connect people with superior, painstakingly tested, beauty products. Following the company’s major success as the fastest-growing online beauty brand in the US, IL MAKIAGE continues to shift millions of customers from offline to online and it recently expanded to the UK, Canada, Germany and Australia. IL MAKIAGE is backed by L Catterton, the leading consumer-focused private equity company in the world. For more information, visit www.ilmakiage.com .

About Voyage81
Founded in 2019, Voyage81 is a deep-tech AI-based computational imaging company that developed a patented software which recovers over 30 channels of hyperspectral information from any simple smartphone camera with no additional hardware, charting a path to revolutionize the beauty and wellness industries. Voyage81, led by alumni of the top elite Israeli intelligence units as well as computer vision PhDs, is also developing in partnership with some of the largest global smartphone manufacturers a hardware-based solution that builds on the company’s hyperspectral software to significantly enhance photos taken in low-light conditions. Voyage81 is backed by True Ventures, Next Gear Ventures, Maniv Mobility and iAngels. For more information, visit www.voyage81.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release

Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye